Inify Laboratories announces application periods for fully guaranteed private placement and fully guaranteed repair issue

Investor News 2025-12-09
STOCKHOLM – 9 December 2025 – Reference is made to the stock exchange announcement made by Inify Laboratories AB (the “Company”) on 12 November 2025, regarding a proposed fully guaranteed share issue generating gross proceeds of approximately NOK 100 million, and the extraordinary general meeting held 4 December 2025 which resolved on the proposed share […]
Read More

Inify Laboratories: Board announces updated timetable for settlement in proposed Private Placement and Repair Issue

Investor News 2025-12-03
STOCKHOLM – December 3, 2025 – The board of directors of Inify Laboratories AB ("Inify" or the "Company") announces its intention to postpone the last date of payment in the Company's proposed share issues announced on November 12, 2025, (the "Private Placement" and the "Repair Issue" respectively). The final payment date is intended to be […]
Read More

Inify Laboratories – notice of Extraordinary General Meeting on December 4, 2025

Annual General Meeting, Investor News 2025-11-12
Stockholm – November 12, 2025 – Inify Laboratories AB (publ), a unique laboratory service that provides cancer diagnostics within pathology, hereby invites its shareholders to Extraordinary General Meeting on December 4, 2025. Please find attached the invitation including attachment, agenda and details on how to register and vote. The invitation is also available on the […]
Read More

Inify Laboratories: Notice of Extraordinary General Meeting and proposed fully guaranteed equity issue with proceeds of NOK 100 million

Annual General Meeting, Investor News 2025-11-12
STOCKHOLM – November 12, 2025 – Inify Laboratories AB ("Inify" or the "Company") will in a separate press release call for an extraordinary general meeting (the "EGM") to be held on December 4, 2025 at 10:00 CET to resolve on a fully guaranteed share issue of a total of 28,571,429 new shares generating gross proceeds of […]
Read More

Correction – Inify Laboratories: First gastrointestinal diagnoses delivered and UK clinical operations on track for launch early 2026

Financial reports, Investor News 2025-10-29
In connection with the publication of the company's Q3 2025 Financial Report, it was discovered that the amount for personnel costs in the parent company's income statement was incorrect. The company is therefore making a correction to the parent company's income statement. STOCKHOLM – October 29, 2025 – Inify Laboratories, a unique laboratory service that […]
Read More

Inify Laboratories: First gastrointestinal diagnoses delivered and UK clinical operations on track for launch early 2026

Investor News 2025-10-29
STOCKHOLM – October 29, 2025 – Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology, expanded its service offering during the third quarter with the addition of a second diagnostic area: gastroenterology. In September, the company launched gastrointestinal diagnostics services in Sweden, successfully diagnosing its first patient samples. “This marks the starting […]
Read More

Inify Laboratories deliver diagnostics for its first patient case in the UK in collaboration with Parkside Frimley

Investor News 2025-06-26
STOCKHOLM – June 26, 2025 – Inify Laboratories, an ultra-modern laboratory service that provides cancer diagnostics within pathology, is proud to announce a significant milestone with the successful processing of its first ever UK case. Under a newly established contract with Parkside Suite, (owned by Frimley Health NHS Foundation Trust). Inify has completed the diagnostic […]
Read More